Skip to content
Interagency Autism Coordinating Committee (IACC)
Autism Research Database
Office of Autism Research Coordination (OARC)
 
Project Element Element Description

Project Title

Project Title

2/3-Atomoxetine placebo and parent training in autism

Principal Investigator

Principal Investigator

Aman, Michael

Description

Description

There have been relatively few randomized clinical trials of pharmacology for attention-deficit/hyperactivity (ADHD) in children with autism spectrum disorders (ASD). Atomoxetine (ATX) was approved by the FDA in January 2003 for treatment of ADHD, but only 4 studies of this drug have been conducted in children with ASD. Behavioral treatments, such as training parents in the use of behavioral interventions (PMT), are also standard treatments for ADHD in typically developing children. While PMT also has long been used in ASD, it has rarely been studied in combination with psychopharmacologic treatment in this population. This three-pronged, 10-week trial in children with ASD will compare atomoxetine vs. placebo, PMT vs. no-PMT, and combined ATX/PMT vs. PMT alone. This trial has the potential to provide answers regarding optimal treatment (both psychosocial and pharmacological) for a sizeable subgroup of children with ASD who experience symptoms of over activity and inattention.

Funder

Funder

National Institutes of Health

Fiscal Year Funding

Fiscal Year Funding

356865

Current Award Period

Current Award Period

2008-2013

Strategic Plan Question

Strategic Plan Question

Question 4: Which Treatments And Interventions Will Help?

Strategic Plan Objective

Strategic Plan Objective

Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4SF. Launch randomized controlled trials of interventions including biological signatures and other measures to predict response, and monitor quality of life and functional outcomes in each of the following groups: o Five trials in infants and toddlers by 2013. IACC Recommended Budget: $30,000,000 over 5 years. o Three trials in school-aged children and/or adolescents by 2013. IACC Recommended Budget: $18,000,000 over 5 years. o Three trials in adults by 2014. IACC Recommended Budget: $18,000,000 over 5 years.

Project Link

Project Link

2/3-Atomoxetine placebo and parent training in autism (External web link)

Institution

Institution

The Ohio State University

State/Country

State/Country

Ohio

Project Number

Project Number

5R01MH079080-05

Federal or Private?

Federal or Private?

Federal

Received ARRA Funding?

Received ARRA Funding?

No

History/Related Projects

History/Related Projects

2/3-Atomoxetine placebo and parent training in autism | 350730 | 2012 | 5R01MH079080-06

 
Back to Top